Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome
- Conditions
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 144
- Registration Number
- NCT01068795
- Locations
- 🇮🇱
Dep. OB/GYN, HaEmek Medical Center, Afula, Israel
Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users
- Conditions
- Interventions
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2010-02-05
- Lead Sponsor
- Hallym University Medical Center
- Target Recruit Count
- 180
- Registration Number
- NCT01063426
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Department of Cardiology and Orthopedic Surgery, Anyang-si, Gyeonggi-do, Korea, Republic of
Taxotere-Enoxaparin-(ENOXA)-Study
- Conditions
- Interventions
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 14
- Registration Number
- NCT01058759
- Locations
- 🇩🇪
Hannover Medical School, Department of Pneumology, Hannover, Lower Saxonia, Germany
B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure
- Conditions
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)
- Conditions
- Interventions
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 62
- Registration Number
- NCT01014403
- Locations
- 🇺🇸
UT-Southwestern Medical Center, Dallas, Texas, United States
🇺🇸East Texas Medical Center, Tyler, Texas, United States
Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2009-09-29
- Lead Sponsor
- Iladevi Cataract and IOL Research Center
- Target Recruit Count
- 23
- Registration Number
- NCT00986076
- Locations
- 🇮🇳
Iladevi Cataract & IOL Research Centre, Ahmedabad, Gujarat, India
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2010-06-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 369
- Registration Number
- NCT00917254
A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)
- Conditions
- Interventions
- First Posted Date
- 2009-06-09
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT00916669
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸North Shore Medical Center, Peabody, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 610
- Registration Number
- NCT00913120
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
- Conditions
- Interventions
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT00908960
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Southern California-Keck School of Medicine, Los Angeles, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.